financetom
Business
financetom
/
Business
/
ATI Q3 Adjusted Earnings Fall, Sales Rise; 2024 EPS Guidance Lowered
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ATI Q3 Adjusted Earnings Fall, Sales Rise; 2024 EPS Guidance Lowered
Nov 3, 2024 1:39 PM

08:02 AM EDT, 10/29/2024 (MT Newswires) -- ATI (ATI) reported Q3 adjusted earnings Tuesday of $0.60 per share, down from $0.64 a year earlier.

Analysts polled by Capital IQ expected $0.67.

Net sales for the quarter ended Sept. 30 were $1.05 billion, compared with $1.03 billion a year earlier.

Analysts surveyed by Capital IQ expected $1.12 billion.

For 2024, the company said it now expects adjusted EPS to be in the range of $2.24 to $2.30, compared with $2.40 to $2.60 previously. Analysts polled by Capital IQ expect $2.48.

ATI shares were down 7.2% in recent premarket activity.

Price: 58.70, Change: -4.52, Percent Change: -7.15

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details
Oct 10, 2024
Indivior PLC ( INDV ) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects third-quarter net revenue of $302 million – $309 million versus the consensus of $289.37 million. Also, Indivior ( INDV ) trimmed its FY24 net revenue outlook to $1.125 billion – $1.165 billion (consensus $1.185 billion) from $1.15 billion –...
Mirum Pharmaceuticals Says Volixibat Gets FDA Breakthrough Therapy Designation in Cholestatic Pruritus
Mirum Pharmaceuticals Says Volixibat Gets FDA Breakthrough Therapy Designation in Cholestatic Pruritus
Oct 10, 2024
09:25 AM EDT, 10/10/2024 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) said Thursday that volixibat has received breakthrough therapy designation from the US Food and Drug Administration as a potential treatment for cholestatic pruritus related to primary biliary cholangitis. The company said the designation is based on the interim analysis of a phase 2b study that demonstrated statistically significant...
Starboard seeks probe after former Pfizer execs pull support for its campaign
Starboard seeks probe after former Pfizer execs pull support for its campaign
Oct 10, 2024
(Reuters) - Starboard Value has asked Pfizer to set up a special committee to investigate allegations that two of its former senior executives were forced to publicly declare support for CEO Albert Bourla, the hedge fund said on Thursday. Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio, who were reportedly helping the activist investor in its plan to push...
Delta Issues Downbeat Fourth-Quarter Earnings Outlook Following Mixed Quarterly Results
Delta Issues Downbeat Fourth-Quarter Earnings Outlook Following Mixed Quarterly Results
Oct 10, 2024
09:24 AM EDT, 10/10/2024 (MT Newswires) -- Delta Air Lines ( DAL ) issued a weak fourth-quarter earnings outlook amid expectations for subdued travel demand around the US Presidential elections in November, as the air carrier's bottom line fell short of market estimates in the prior three-month period while revenue beat Wall Street forecasts. The airline anticipates adjusted earnings to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved